SELECT * FROM `stock_list` WHERE `symbol` = "OVID" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
SELECT * FROM `stock_list` where symbol='OVID' AND exchange = 'NAS' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "OVID" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 OVID (Ovid Therapeutics) Marketable Securities
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (NAS:OVID) » Definitions » Marketable Securities

Ovid Therapeutics (Ovid Therapeutics) Marketable Securities : $78.79 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Ovid Therapeutics's Marketable Securities for the quarter that ended in Dec. 2023 was $78.79 Mil.

Ovid Therapeutics's annual Marketable Securities increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($84.13 Mil) but then declined from Dec. 2022 ($84.13 Mil) to Dec. 2023 ($78.79 Mil).

Ovid Therapeutics Marketable Securities Historical Data

The historical data trend for Ovid Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovid Therapeutics Marketable Securities Chart

Ovid Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 34.84 - - 84.13 78.79

Ovid Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.13 54.67 24.89 29.64 78.79

Ovid Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Ovid Therapeutics  (NAS:OVID) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Ovid Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovid Therapeutics (Ovid Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (NAS:OVID) » Definitions » Marketable Securities
Comparable Companies
VNDA IGMS NRIX AVIR DRTS YMAB XERS MGTX CMPX RPHM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
1OT:Germany
Address
441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Website
https://www.ovidrx.com
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Executives
Jason Tardio officer: Chief Commercial Officer 1460 BROADWAY, NEW YORK NY 10036
Takeda Pharmaceuticals U.s.a., Inc. 10 percent owner ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Kevin Joseph Fitzgerald director C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Amit Rakhit officer: CMO and PMO C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Robert Michael Poole director 200 W. HIGHLAND DR., #303, SEATTLE WA 98119
Jeffrey A Rona officer: Chief Business Officer 500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeremy M Levin director, 10 percent owner, officer: CEO
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Thomas Michael Perone officer: SVP, General Counsel 1460 BROADWAY, NEW YORK NY 10036
Karen Bernstein director C/O VITAE PHARMACEUTICLS, INC., 502 WEST OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Douglas E Williams director C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Ana Ward officer: SVP and General Counsel C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Timothy Daly officer: VP, Finance & Corp. Controller 20 KINGSBRIDGE ROAD, PISCATAWAY NJ 08854